Skip to Main Content

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood
Blood Advances
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current issue
- All Issues
CME
About

Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2012, Issue 1

December 8 2012

In this Issue

Ham-Wasserman Lecture
3 P’s in a Pod
Acute Myeloid Leukemia: Newly Discovered Genes, Screens (for Minimal Residual Disease), and Therapeutic Means
Advances in the Pathogenesis and Treatment of Myelodysplastic Syndromes
Chronic Lymphocytic Leukemia: Can New Prognostic Factors Guide New Therapeutic Approaches?
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
Dynamic Discoveries and Directions in Pediatric Leukemias
Everyday Bleeding Disorders
Evidence-Based Approaches to Cytopenias
Hematologic Diseases in Pregnancy
Hematopoietic Stem Cell Transplantation I: Exploiting Alternative Donors
Hematopoietic Stem Cell Transplantation II: Toward Safer Allogeneic Transplantation
Hemoglobinopathies: New Frontiers and Insights
Immune Dysregulation
Insights into Biology and Refinement of Treatment Strategies in Hodgkin Lymphoma
Keeping Pace with Advances in Myeloma
Landscape Changes and Challenges in Hemophilia
New Insights into the Genetic Pathogenesis of Acute Lymphocytic Leukemia and New Treatment Strategies
Non-Hodgkin Lymphoma I: Changing Therapeutic Strategies in Aggressive Lymphomas
Non-Hodgkin Lymphoma II: Understanding the Indolent Lymphomas
Not So ‘Benign’ Hematologic Issues in Children
Pearls and Pitfalls in the Hematology Lab: Clotting and Bleeding
Pearls and Pitfalls in the Hematology Lab: Updates on Cellular Diagnostics
Pediatric Issues in Platelet Transfusions
Perioperative Hematology: To Bleed or Not To Bleed
The New Era in Antithrombotic Therapy
The Spectrum of JAK2-Positive Myeloproliferative Neoplasms: Complications and Therapeutic Advances
The Spectrum of Plasma Cell Dyscrasias
The Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndromes: New Insights and New Treatments
Thrombosis in Challenging Populations
Untangling Uncommon Lymphoproliferative Disorders
ERRATA

54th ASH® Annual Meeting and Exposition

Ham-Wasserman Lecture

Treatment of acute myeloid leukemia: are we making progress?

Alan K. Burnett

3 P’s in a Pod

Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines

Jeffrey L. Winters

Gaucher disease and other storage disorders

Gregory A. Grabowski

The porphyrias: advances in diagnosis and treatment

Manisha Balwani,Robert J. Desnick

Acute Myeloid Leukemia: Newly Discovered Genes, Screens (for Minimal Residual Disease), and Therapeutic Means

How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?

Jay P. Patel,Ross L. Levine

Minimal residual disease in acute myeloid leukemia: coming of age

Elisabeth Paietta

The prevalent predicament of relapsed acute myeloid leukemia

Jeffrey Szer

Advances in the Pathogenesis and Treatment of Myelodysplastic Syndromes

Myelodysplastic syndromes: who and when in the course of disease to transplant

Ghulam J. Mufti,Victoria Potter

Interpreting new molecular genetics in myelodysplastic syndromes

Omar Abdel-Wahab,Maria E. Figueroa

Novel therapeutic strategies: hypomethylating agents and beyond

Valeria Santini

In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

Ronan Swords,Valeria Santini

Chronic Lymphocytic Leukemia: Can New Prognostic Factors Guide New Therapeutic Approaches?

Implications of new prognostic markers in chronic lymphocytic leukemia

Nicholas Chiorazzi

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

Adrian Wiestner

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Paolo Ghia

Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy

Monitoring after successful therapy for chronic myeloid leukemia

Susan Branford

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

David T. Yeung,Susan Branford

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia

David Marin

Is going for cure in chronic myeloid leukemia possible and justifiable?

François-Xavier Mahon

Dynamic Discoveries and Directions in Pediatric Leukemias

Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?

Elizabeth A. Raetz,Teena Bhatla

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient

Martin Schrappe

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen

Renier J. Brentjens,Kevin J. Curran

Everyday Bleeding Disorders

Bleeding scores: are they really useful?

Sarah H. O'Brien

Measuring bleeding as an outcome in clinical trials of prophylactic platelet transfusions

Rachel S. Bercovitz,Sarah H. O'Brien

Making a diagnosis of VWD

Brian R. Branchford,Jorge Di Paola

Hemostatic defects in liver and renal dysfunction

Pier Mannuccio Mannucci,Armando Tripodi

Evidence-Based Approaches to Cytopenias

How to approach neutropenia

Laurence A. Boxer

How to approach chronic anemia

Mark J. Koury,Melissa Rhodes

How to approach thrombocytopenia

Roberto Stasi

Hematologic Diseases in Pregnancy

Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…?

Terry B. Gernsheimer

Thrombosis in pregnancy: updates in diagnosis and management

Ian A. Greer

Baby on board: what you need to know about pregnancy in the hemoglobinopathies

Rakhi P. Naik,Sophie Lanzkron

Hematopoietic Stem Cell Transplantation I: Exploiting Alternative Donors

Umbilical cord blood transplantation: a maturing technology

Betul Oran,Elizabeth Shpall

Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation?

Andrea Bacigalupo

Haploidentical transplantation for hematologic malignancies: where do we stand?

Ephraim J. Fuchs

Hematopoietic Stem Cell Transplantation II: Toward Safer Allogeneic Transplantation

Do different conditioning regimens really make a difference?

Didier Blaise,Luca Castagna

Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?

Tanya Siddiqi,Didier Blaise

Are we making progress in GVHD prophylaxis and treatment?

Steven Z. Pavletic,Daniel H. Fowler

Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge

Kieren A. Marr

Hemoglobinopathies: New Frontiers and Insights

Emerging ‘A’ therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine

Elliott Vichinsky

Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies

Emmanuel Payen,Philippe Leboulch

Health-related quality of life in patients with hemoglobinopathies

Julie A. Panepinto

What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease?

Deepika S. Darbari,Julie A. Panepinto

Immune Dysregulation

Aplastic anemia: therapeutic updates in immunosuppression and transplantation

Phillip Scheinberg

The many faces of common variable immunodeficiency

Charlotte Cunningham-Rundles

Pathogenesis in immune thrombocytopenia: new insights

Jill Johnsen

Insights into Biology and Refinement of Treatment Strategies in Hodgkin Lymphoma

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy

Ralph M. Meyer,Richard T. Hoppe

How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?

Martin Hutchings

New insights in the biology of Hodgkin lymphoma

Ralf Küppers

Keeping Pace with Advances in Myeloma

Have drug combinations supplanted stem cell transplantation in myeloma?

Antonio Palumbo,Federica Cavallo

How to use new biology to guide therapy in multiple myeloma

Gareth J. Morgan,Martin F. Kaiser

What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?

Frederick L. Locke,Gareth J. Morgan

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

S. Vincent Rajkumar

Landscape Changes and Challenges in Hemophilia

New challenges in hemophilia: long-term outcomes and complications

Guy Young

Therapeutic challenges in acquired factor VIII deficiency

Peter W. Collins

The gene therapy journey for hemophilia: are we there yet?

Katherine A. High

New Insights into the Genetic Pathogenesis of Acute Lymphocytic Leukemia and New Treatment Strategies

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Hillard M. Lazarus,Anjali S. Advani

The molecular genetic makeup of acute lymphoblastic leukemia

Charles G. Mullighan

Non-Hodgkin Lymphoma I: Changing Therapeutic Strategies in Aggressive Lymphomas

Interim PET-CT in the management of diffuse large B-cell lymphoma

Craig H. Moskowitz

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma

Laurie H. Sehn

Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?

Christian Gisselbrecht

Non-Hodgkin Lymphoma II: Understanding the Indolent Lymphomas

Changing role of stem cell transplantation in follicular lymphoma

Ginna G. Laport

The many faces of marginal zone lymphoma

Pier Luigi Zinzani

Is there a role for “watch and wait” in follicular lymphoma in the rituximab era?

Brad Kahl

Not So ‘Benign’ Hematologic Issues in Children

Updates in thrombosis in pediatrics: where are we after 20 years?

Anthony K. C. Chan,Paul Monagle

Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics

Janna M. Journeycake

The conundrum of neonatal coagulopathy

Shoshana Revel-Vilk

Pearls and Pitfalls in the Hematology Lab: Clotting and Bleeding

Dos and don'ts in diagnosing antiphospholipid syndrome

Jacob H. Rand,Lucia R. Wolgast

Coagulation assays and anticoagulant monitoring

Dorothy M. (Adcock) Funk

Is my patient a bleeder? A diagnostic framework for mild bleeding disorders

Teresa Quiroga,Diego Mezzano

Pearls and Pitfalls in the Hematology Lab: Updates on Cellular Diagnostics

Malignant or benign leukocytosis

Tracy I. George

Low blood counts: immune mediated, idiopathic, or myelodysplasia

Peter Valent

Anemias beyond B12 and iron deficiency: the buzz about other B's, elementary, and nonelementary problems

Ralph Green

Pediatric Issues in Platelet Transfusions

Thrombocytopenia and bleeding in pediatric oncology patients

Rachel S. Bercovitz,Cassandra D. Josephson

Platelets in the neonatal period: developmental differences in platelet production, function, and hemostasis and the potential impact of therapies

Martha Sola-Visner

Thrombocytopenia, bleeding, and use of platelet transfusions in sick neonates

Simon J. Stanworth

Perioperative Hematology: To Bleed or Not To Bleed

Pharmacologic tools to reduce bleeding in surgery

Sam Schulman

Assessment and management of massive bleeding: coagulation assessment, pharmacologic strategies, and transfusion management

Jeannie L. Callum,Sandro Rizoli

Perioperative management of patients on chronic antithrombotic therapy

Thomas L. Ortel

The New Era in Antithrombotic Therapy

New oral anticoagulants: which one should my patient use?

Jeffrey I. Weitz,Peter L. Gross

Is there a role for warfarin anymore?

Alan Jacobson

Antithrombotic therapy: triple therapy or triple threat?

Jessica Mega,Edward T. Carreras

The Spectrum of JAK2-Positive Myeloproliferative Neoplasms: Complications and Therapeutic Advances

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?

Stefan N. Constantinescu,William Vainchenker

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian

Is there a role for the use of IFN-α in primary myelofibrosis?

Huong (Marie) Nguyen,Jean-Jacques Kiladjian

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga,Marina Marchetti

The Spectrum of Plasma Cell Dyscrasias

Case vignettes and other brain teasers of monoclonal gammopathies

Morie Gertz,Francis K. Buadi

Are you sure this is Waldenström macroglobulinemia?

Irene M. Ghobrial

Differential diagnosis of monoclonal gammopathy of undetermined significance

Giampaolo Merlini,Giovanni Palladini

The Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndromes: New Insights and New Treatments

Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes

James N. George,Zayd L. Al-Nouri

Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura

Johanna A. Kremer Hovinga,Bernhard Lämmle

Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?

Carla M. Nester,Christie P. Thomas

Thrombosis in Challenging Populations

Cancer-associated thrombosis: updates and controversies

Alok A. Khorana

Thromboprophylaxis in nonsurgical patients

Michael B. Streiff,Brandyn D. Lau

Catheter-related thrombosis: lifeline or a pain in the neck?

Pieter W. Kamphuisen,Agnes Y. Y. Lee

Untangling Uncommon Lymphoproliferative Disorders

B- and T-cell prolymphocytic leukemia: antibody approaches

Claire Dearden

Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment

Dan Zhang,Thomas P. Loughran, Jr

Immunoconjugates and new molecular targets in hairy cell leukemia

Robert J. Kreitman

ERRATA

Arnason JE, Brown JR. Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:119–120.

Cover Image

Cover Image

Cover: Colored scanning electron micrograph (SEM) of red blood cells (erythrocytes, orange) and B lymphocyte white blood cells (white) from a patient with leukemia. Reprinted by permission from © Steve Gschmeissner/Corbis.
Front Matter
Table of Contents
Advertising
Editorial Board

Latest
Most Read
Most Cited

Clinical screening for Ph-like ALL and the developing role of TKIs

Perioperative hemostasis for patients with hemophilia

Evidence-based management of pregnant women with sickle cell disease in high-income countries

Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy

Optimal approach to T-cell ALL

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright ©2023 by American Society of Hematology

Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account